#17 Bacteriophage Therapy against Cholera (Minmin Yen‪)‬ Holobiont

Dr Minmin Yen (PhD) is the co-founder and CEO of PhagePro, an early stage bio-tech company spun out of the Camilli lab at Tufts University developing bacteriophage prophylactics against cholera, a diarrhoeal disease caused by Vibrio cholerae. Minimin Yen has been recognised by the MIT's Tech Review as 35 innovators under 35 for her work bridging biological engineering and public health. 

In this conversation we discuss:


The evidence that bacteriophages play a role in cholera epidemics
The strategy of delivering lytic bacteriophages to prevent person-person transmission
How we can compound the emergence of resistance in cholera bacteria
Building trust in communities for adoption of experimental therapies
The challenges of developing a biotech and manufacturing bacteriophage prophylactics

Link to the PhagePro website: https://www.phageproinc.com

Minmin Yen's MIT Tech Review article : https://www.innovatorsunder35.com/the-list/minmin-yen/